Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Results (paragraph on characteristics of included studies) and Table 1 |
Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | Results (paragraph on characteristics of included studies) and Table 1 |
Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: a) simple summary data for each intervention group b) effect estimates and confidence intervals, ideally with a forest plot. | Results (paragraph on characteristics of included studies), Table 2, Figure 2, Table S2, Figure S1 |
Synthesis of results | 21 | Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and measures of consistency | Results (paragraph on effect of IPP/VPP on blood pressure) |
Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | Results (paragraph on influence of individual studies and publication bias), Figure 7 and Figure S4 |
Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | Results (paragraph on exploration of heterogeneity & subgroup meta-analyses), Figures 3-6, Figures S2 and Figures S3 |
DISCUSSION |
| ||
Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | Discussion |
Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | Discussion |
Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | Discussion |
FUNDING |
| ||
Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Paragraph on acknowledgments |